Quanterix Receives FDA Emergency Use Authorization for SARS-CoV-2 N Protein Antigen Test
Quanterix Receives FDA Emergency Use Authorization for SARS-CoV-2 N Protein Antigen Test Quanterix Receives FDA Emergency Use Authorization for SARS-CoV-2 N Protein Antigen Test Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that the Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for its Simoa SARS-CoV-2 N Protein Antigen Test that can be run on the Simoa HD-X Analyzer, a fully automated high-throughput immunoassay instrument. The Simoa SARS-CoV-2 N Protein Antigen...
Source: globalbankingandfinance.com